Department of Medicine, Division of Infectious Diseases, Vanderbilt University Medical Center, Tennessee Valley Veterans Health System/Nashville Veterans Affairs Hospital, A2200 MCN, 1161 21st Ave S, Nashville, TN, 37232, USA.
Curr HIV/AIDS Rep. 2018 Jun;15(3):223-232. doi: 10.1007/s11904-018-0399-7.
This narrative review summarizes recent data on factors associated with insulin resistance (IR) in adults with HIV, including contemporary antiretroviral therapy (ART).
IR remains common in persons with HIV, even those receiving contemporary ART. Generalized and abdominal obesity and ectopic fat are correlates of IR, and emerging data have identified associations with biomarkers of inflammation and immune activation. Small studies suggest associations between mitochondria and IR. In ART-naïve individuals, IR increased within 4 weeks of starting ART in persons receiving contemporary boosted protease inhibitors or an integrase inhibitor. The importance of IR in non-diabetic persons with HIV will continue to grow as the population ages and obesity increases. Non-invasive estimates of IR appear to perform well in persons with HIV, but clinically relevant cutoffs are uncertain. Unexpected metabolic effects of newer HIV integrase inhibitors have been reported; thus, careful observation for and studies of IR are still warranted.
本文对与 HIV 感染者(包括接受当代抗逆转录病毒治疗(ART)者)相关的胰岛素抵抗(IR)的因素进行了综述。
即使接受当代 ART,HIV 感染者仍普遍存在 IR。全身性和腹部肥胖及异位脂肪与 IR 相关,新兴数据还发现其与炎症和免疫激活的生物标志物相关。一些小型研究提示 IR 与线粒体之间存在关联。在未接受 ART 的个体中,接受当代增效蛋白酶抑制剂或整合酶抑制剂治疗者在开始 ART 的 4 周内 IR 增加。随着人群老龄化和肥胖增加,非糖尿病 HIV 感染者中 IR 的重要性将继续增加。非侵入性的 IR 估计在 HIV 感染者中表现良好,但临床相关的截断值尚不确定。新型 HIV 整合酶抑制剂有意外的代谢作用,因此仍需要对 IR 进行仔细观察和研究。